Ionis Pharmaceuticals, Inc. (IONS) shares rose 2.58% to $46.06 after the company and Otsuka Pharmaceutical announced positive topline results from the Phase 3 FUSION study of ulefnersen, an experimental treatment for a rare genetic form of amyotrophic lateral sclerosis (ALS). The trial met its primary endpoint, a result that strengthens Ionis' neurological pipeline and supports the next regulatory steps for the therapy.

Phase 3 FUSION Trial Meets Primary Endpoint

Ionis and Otsuka reported the topline results from FUSION, a Phase 3 study evaluating ulefnersen in patients with ALS caused by mutations in the fused in sarcoma gene, a form of the disease known as FUS-ALS. Researchers developed ulefnersen to target the genetic cause of this rare and rapidly progressing condition. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.

The study met its primary endpoint after demonstrating statistically significant improvements over placebo across measures of function and survival. The assessment covered death, permanent ventilation, rescue treatment, and changes on the ALS Functional Rating Scale Revised, a standard measure of patient functioning. primary analysis produced a p-value of 0.0005, supporting the statistical significance of the outcome. Endpoints that combine survival-related events with functional change are a standard way ALS trials capture clinically meaningful benefit, since the disease affects both day-to-day function and survival.

Ulefnersen also delivered statistically significant improvements across several important secondary endpoints. These included serum neurofilament light chain levels, a biomarker of neurodegeneration, and the time to death, ventilation, rescue, or disease-related withdrawal. Neurofilament light chain is widely used in neurodegeneration research as a marker of nerve cell injury, giving researchers a biological readout to track alongside clinical measures. The companies reported favorable safety and tolerability, with most adverse events remaining mild or moderate in severity.

Results Advance Ulefnersen Toward Regulatory Review

The successful trial provides Ionis and Otsuka with substantial clinical evidence as they prepare for discussions with regulators around the world. Otsuka plans to review the FUSION findings with the U.S. Food and Drug Administration and will also discuss potential expedited submission pathways with other health authorities. Regulators can grant expedited pathways for therapies aimed at serious diseases, and such designations, when awarded, can shorten the time between a filing and a decision.

Both companies intend to present the detailed FUSION results at a future medical meeting and to submit the complete findings for publication in a peer-reviewed medical journal. Additional prespecified and exploratory analyses will further examine ulefnersen's effects across the study population. Those disclosures, together with the outcome of the FDA discussions, are the next milestones to watch as the program moves toward a potential regulatory submission.

Ionis licensed ulefnersen to Otsuka in 2024 through a collaborative development and licensing agreement. Under the deal, Ionis received an upfront payment and remains eligible for additional regulatory and commercial milestone payments. The agreement also provides Ionis with tiered royalties on future net sales if the treatment reaches the market. Licensing structures of this kind are common in biotech, pairing a discovery-focused company with a larger partner that funds late-stage development and commercialization while the originator retains milestone and royalty upside.

FUSION Design and Ionis' Genetic ALS Program

FUSION employed a global, randomized, double-blind, placebo-controlled design to evaluate ulefnersen's safety and effectiveness in FUS-ALS. Participants received either ulefnersen or placebo during a 72-week blinded treatment period, after which they entered an open-label extension in which all participants received the drug. Open-label extensions are a common feature of rare-disease trials, allowing participants to continue on or cross over to the experimental therapy once the blinded period ends.

The primary analysis included 73 participants and combined clinical function with several survival-related outcomes. Researchers additionally evaluated respiratory function, muscle strength, quality of life, and key biological markers. These measures will help define the treatment's broader clinical profile during further analysis.

The program expands Ionis' work in genetically targeted treatments for rare forms of ALS. The company's earlier neurological development included QALSODY, an approved therapy directed at a different genetic cause of the disease. With FUSION, ulefnersen adds a successful Phase 3 program focused specifically on patients with FUS-related ALS, extending Ionis' genetically targeted approach to a second defined ALS population.